TRCT
NVCT icon

Tower Research Capital (TRC)’s Nuvectis Pharma NVCT Stock Holding History

Tower Research Capital (TRC)’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.6K Sell
1,611
-4,151
-72% -$46.5K ﹤0.01% 3188
2026
Q1 		$44.5K Buy
5,762
+4,344
+306% +$37.2K ﹤0.01% 2845
2025
Q4 		$10.7K Sell
1,418
-2,431
-63% -$15.8K ﹤0.01% 3720
2025
Q3 		$23.2K Buy
+3,849
New +$26.5K ﹤0.01% 3175
2024
Q4 		– Sell
-588
Closed -$3.7K – 5906
2024
Q3 		$3.7K Sell
588
-5,408
-90% -$35.6K ﹤0.01% 4792
2024
Q2 		$38K Buy
5,996
+5,145
+605% +$35K ﹤0.01% 3306
2024
Q1 		$6.98K Sell
851
-427
-33% -$3.63K ﹤0.01% 4284
2023
Q4 		$10.7K Sell
1,278
-6,004
-82% -$53.5K ﹤0.01% 4216
2023
Q3 		$93.9K Buy
7,282
+6,739
+1,241% +$97.6K ﹤0.01% 2026
2023
Q2 		$8.67K Buy
543
+293
+117% +$4.68K ﹤0.01% 4389
2023
Q1 		$3K Sell
250
-1,109
-82% -$11.2K ﹤0.01% 5220
2022
Q4 		$10K Sell
1,359
-2,693
-66% -$19.3K ﹤0.01% 4041
2022
Q3 		$29K Buy
4,052
+2,773
+217% +$25.8K ﹤0.01% 3629
2022
Q2 		$14K Sell
1,279
-471
-27% -$5.82K ﹤0.01% 4153
2022
Q1 		$13K Buy
+1,750
New +$12.2K ﹤0.01% 3990

Other funds holding NVCT

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $193M AUM 233.09% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Tower Research Capital (TRC)'s NVCT Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Nuvectis Pharma (NVCT) stake by 72% in Q2 2026, selling an estimated $46.5K and leaving 1,611 shares worth $29.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3188.

Tower Research Capital (TRC) first reported a position in NVCT in Q1 2022 and has held it in 15 quarters since. The position peaked at $93.9K in Q3 2023. 83 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

  • Tower Research Capital (TRC) held 1,611 shares of Nuvectis Pharma worth $29.6K as of Q2 2026.
  • Tower Research Capital (TRC) sold 4,151 Nuvectis Pharma shares in Q2 2026, an estimated $46.5K.
  • Nuvectis Pharma made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3188 holding.
  • Tower Research Capital (TRC) first reported a position in Nuvectis Pharma in Q1 2022 and has held it in 15 quarters since.
  • Tower Research Capital (TRC)'s Nuvectis Pharma position peaked at $93.9K in Q3 2023.
  • 83 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.